GlaxoSmithKline: Asthma trials

The registry lists 261 Asthma studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 132 have results posted.

Phase 1 63Phase 2 59Phase 3 61Phase 4 53No phase 26(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fall Epidemic Viral Pediatric StudyCompletedNCT01192178Phase 4Results posted
• Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent AsthmaCompletedNCT01181895Phase 3Results posted
• Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent AsthmaticsCompletedNCT01165138Phase 3Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and AdolescentsCompletedNCT01159912Phase 3Results posted
• Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of AgeCompletedNCT01156792Phase 2Results posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and AdolescentsCompletedNCT01147848Phase 3Results posted
• Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once DailyCompletedNCT01147744Phase 2Results posted
• Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent AsthmaticsCompletedNCT01134042Phase 3Results posted
• Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic ResponseCompletedNCT01128595Phase 2Results posted
• Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic ResponseCompletedNCT01128569Phase 2Results posted
• Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) AxisCompletedNCT01086410Phase 3Results posted
• Asthma Exacerbation StudyCompletedNCT01086384Phase 3Results posted
• Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety StudyCompletedNCT01018186Phase 3Results posted
• Dose Ranging Efficacy And Safety With Mepolizumab in Severe AsthmaCompletedNCT01000506Phase 2Results posted
• Efficacy and Safety Study in Subjects With AsthmaCompletedNCT00980200Phase 2Results posted
• A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild AsthmaticsCompletedNCT00857857Phase 2Results posted
• GSK2190915 Moderate to Severe Asthma StudyTerminatedNCT00850642Phase 2Results posted
• Efficacy and Safety Study of GSK679586 in Patients With Severe AsthmaCompletedNCT00843193Phase 2Results posted
• A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following ExerciseCompletedNCT00812929Phase 2Results posted
• Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of AsthmaCompletedNCT00766090Phase 2Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.CompletedNCT00603746Phase 2Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.CompletedNCT00603382Phase 2Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.CompletedNCT00603278Phase 2Results posted
• Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.CompletedNCT00600171Phase 2Results posted
• Study Of Fluticasone Propionate/Salmeterol In Asthmatic SubjectsCompletedNCT00517634Phase 4Results posted
• Study Of RV-39 In Patients Who Also Have AsthmaTerminatedNCT00503009Phase 4Results posted
• SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In AdultsCompletedNCT00461500Phase 4Results posted
• SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)CompletedNCT00455923Phase 4Results posted
• A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With AsthmaCompletedNCT00452699Phase 4Results posted
• A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With AsthmaCompletedNCT00452348Phase 4Results posted
• Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-CompletedNCT00449046Phase 3Results posted
• Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial AsthmaCompletedNCT00448435Phase 3Results posted
• A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With AsthmaCompletedNCT00441441Phase 3Results posted
• Results Of Patient Rated Asthma Control Test In Comparison To Diary Card DataCompletedNCT00363480Phase 4Results posted
• Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled CorticosteroidsCompletedNCT00353873Phase 4Results posted
• Study Of Allergic Rhinitis In Patients Who Also Have AsthmaCompletedNCT00296491Phase 4Results posted
• Treatment Of Symptomatic Asthma In ChildrenCompletedNCT00197106Phase 4Results posted
• A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseCompletedNCT00118716Phase 4Results posted
• A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283Active, not recruitingNCT07712393Phase 1
• A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaActive, not recruitingNCT06748053Phase 2
• Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple IndicationsCompletedNCT06488703
• REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyActive, not recruitingNCT06041386Phase 4
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaActive, not recruitingNCT05757102Phase 3
• A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic AsthmaWithdrawnNCT03707678Phase 2
• Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World SettingCompletedNCT03595930
• Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaWithdrawnNCT03376932Phase 3
• The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on AsthmaWithdrawnNCT03363191Phase 4
• A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With AsthmaCompletedNCT03344406
• Arnuity® Ellipta® Drug Use InvestigationCompletedNCT03184480
• The Extended Salford Lung Study ("Ex-SLS") Data Access ProjectCompletedNCT03152669
• Prevalence of Severe Asthma in Spanish HospitalsCompletedNCT03137043
• A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled AsthmaWithdrawnNCT02794519Phase 2
• Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting ConditionsCompletedNCT02658422Phase 1
• Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & AsthmaCompletedNCT02619357Phase 1
• Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02302417Phase 2
• Cross-sectional Study for Identification and Description of Severe Asthma PatientsCompletedNCT02293265Phase 3
• GSK2190915A - Bioavailability StudyCompletedNCT02224521Phase 1
• A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® InhalerWithdrawnNCT02218762Phase 1
• Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® PresentationCompletedNCT02218723Phase 1
• To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With AsthmaCompletedNCT02195284Phase 4
• ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With AsthmaCompletedNCT02135718
• A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus SpacerCompletedNCT02045953Phase 1
• Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.CompletedNCT01984086Phase 1
• Bioequivalence Study of Montelukast 10 mg TabletsCompletedNCT01943942Phase 1
• ROTAHALER Device Optimization StudyCompletedNCT01890863Phase 1
• Bioequivalence Study of Montelukast 5 mg ChewableCompletedNCT01863654Phase 1
• A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With AsthmaCompletedNCT01837316Phase 1
• To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)CompletedNCT01725685Phase 1
• A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.WithdrawnNCT01721135Phase 1
• Relovair PD PK in Chinese Healthy SubjectsCompletedNCT01711463Phase 1
• WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and OutcomesCompletedNCT01681979
• A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)CompletedNCT01669070Phase 1
• Aura Adolescent PK Study GSK2829332WithdrawnNCT01653483Phase 2
• WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial InfarctionCompletedNCT01636726
• A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory AllergiesCompletedNCT01607372Phase 2
• A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male VolunteersCompletedNCT01563042Phase 1
• A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/SalmeterolCompletedNCT01540708Phase 1
• A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.CompletedNCT01499446Phase 2
• Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol CombinationCompletedNCT01485445Phase 1
• Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECTCompletedNCT01476059Phase 4
• GSK2190915 Neutrophilic Asthma StudyCompletedNCT01471665Phase 2
• Japanese Phase 1 Study of MepolizumabCompletedNCT01471327Phase 1
• Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557CompletedNCT01462617Phase 1
• A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With ExerciseWithdrawnNCT01435902Phase 3
• Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma PatientsCompletedNCT01431924
• A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of RosuvastatinCompletedNCT01411111Phase 1
• European Cost of Asthma TreatmentCompletedNCT01376219
• GSK2239633 FTIH StudyCompletedNCT01371812Phase 1
• Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)CompletedNCT01332422
• Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled CorticosteroidsCompletedNCT01332344
• GSK BHR Study (Sont - Second Study)CompletedNCT01324362Phase 4
• A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915ACompletedNCT01318980Phase 1
• Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy SubjectsCompletedNCT01299558Phase 1
• GSK2190915 Pediatric StudyWithdrawnNCT01286844Phase 2
• A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.CompletedNCT01266941Phase 1
• Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for AsthmaCompletedNCT01248975Phase 2
• A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)CompletedNCT01245426Phase 2
• Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an InhalerCompletedNCT01213849Phase 1
• Corrected QT (QTc) Study With Flucticasone Furoate and GW642444CompletedNCT01209026Phase 1